Surfactant Therapy for Acute Respiratory Failure in Children
Author Information
Author(s): Duffett Mark, Choong Karen, Ng Vivian, Randolph Adrienne, Cook Deborah J
Primary Institution: McMaster Children's Hospital
Hypothesis
What is the effect of exogenous pulmonary surfactant on all-cause mortality in children mechanically ventilated for acute respiratory failure?
Conclusion
Surfactant use decreased mortality, was associated with more ventilator-free days and reduced the duration of ventilation.
Supporting Evidence
- Surfactant use reduced mortality (relative risk = 0.7).
- Surfactant was associated with increased ventilator-free days (weighted mean difference = 2.5 days).
- Surfactant reduced the duration of ventilation (weighted mean difference = 2.3 days).
- No serious adverse events were reported.
Takeaway
Surfactant helps sick kids breathe better and live longer when they have serious lung problems.
Methodology
Systematic review and meta-analysis of randomized controlled trials of surfactant therapy in mechanically ventilated children.
Potential Biases
Potential bias due to lack of blinding in some trials and differences in patient characteristics.
Limitations
Most trials enrolled small numbers of children, and further well-designed multicentre trials are needed.
Participant Demographics
Children with acute respiratory failure, including those with bronchiolitis and ARDS.
Statistical Information
P-Value
0.04
Confidence Interval
0.4 to 0.97
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website